产品库

现货供应,美国进口,Vorinostat (SAHA) ,目录号 S1047,CAS号:149647-78-9, HDAC-HSP-Aurora ,HDAC YZ剂,HDAC inhibitors

产品信息
  • 信号转导通路:  HDAC-HSP-Aurora >> HDAC >> HDAC YZ剂 >> 
    技术数据:
    分子量(MW): 264.3
    化学式:

    C14H20N2O3

    溶解度: DMSO ≥53mg/mL   Water <1mg/mL   Ethanol ≥5mg/mL
    纯度: >99%
    稳定性: at -20℃ 2 years
    CAS号: 149647-78-9
    生物活性

    Suberoylanilide hydroxamic acid (SAHA). Tumor suppressor genes are often silenced in human cancer; this can occur by transcriptional repression by deacetylation in the promoter regions, mediated by histone deacetylase (HDAC). HDAC inhibitors can block cancer cell growth by restoring expression of tumor suppressor genes. Vorinostat efficiently suppressed MES-SA cell growth at a low dosage (3 μM) already after 24 hours treatment. Decrease of cell survival was even more pronounced after prolonged treatment and reached 9% and 2% after 48 and 72 hours of treatment, respectively. Colony forming capability of MES-SA cells treated with 3 μM vorinostat for 24 and 48 hours was significantly diminished and blocked after 72 hours. [2]

    参考文献
    • Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells Takashi Kumagai,Naoki Wakimoto,et al. Int. J. Cancer 2007;121:656–665
    • Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo Andelko Hrzenjak,Farid Moinfar,et al. Molecular Cance 2010;9:49
    客户反馈数据

    Vorinostat inhibits the tumor growth. NOD ⁄ SCID-B2m) ⁄ )mice were injected s.c. with 1 ・ 106 MyLa2059 cells into both flanks. When the mice had developed established palpable tumors treatment was initiated (day 1). The mice received either vehicle (black line) or 60 mg ⁄ kg vorinostat (grey line) i.p. five days a week. In total, there were four mice in the group receiving vehicle and three mice in the group receiving vorinostat. The length and width of the tumors were measured continuously until the experiment was terminated on day 20 post treatment initiation. The tumor volume was calculated using the formula V = (a ・ b2) ⁄ 2, where a defines the length (mm) and b the width (mm) of the tumor. The histogram shows the average tumor volume per flank ± SEM. * denotes a significant difference (P < 0.05) in the average tumor volume per flank between mice treated with vehicle and vorinostat at the given time-point both by using a one-tailed two samples test with Welch’s correction and a Mann–Whitney U test.

     

     

    Vorinostat promotes C2C12 differentiation.In the image, the red is the myotube indicating differentiation ,the blue is the nuclei.

     

     

    Western blot analysis of Acetyl-H3 and H3. 0-20μM SAHA was added.

     

     

    SAHA induces the down-regulation of cFLIP expression and promotes TRAIL-mediated activation of a mitochondrial-operated apoptotic pathway. a BT-474 cells were treated as indicated in Fig. 1 and the cells were then harvested to analyse caspase-8, Bid, caspase-9, caspase-3 and PARP expression, using GAPDH as the protein loading control. b BT-474 cells were treated with SAHA for 8 h at the doses indicated and subsequently, the cells were harvested and the apoptosis-related proteins were analysed in western blots as described in the “Materials and Methods”. The results shown are representative of at least three independent experiments

    Treatment with SAHA sensitizes breast cancer cells to TRAILinduced apoptosis. BT-474 and MDA-MB-231 cells were incubated for 8 h with SAHA at the doses indicated. After this time, TRAIL (500 ng/ml) was added to some of the cultures for an additional 15 h. Apoptosis was measured as the percentage of cells with subG1 DNA content as described in the “Materials and methods”. The results show the mean and S.E.M. of three independent experiments

    SAHA facilitates the Itch/AIP4-independent proteasomal degradation of cFLIP proteins in breast cancer cells. a BT-474 cells were treated with SAHA (5 μM) for 8 h in the presence or absence of the proteasome inhibitors MG132 or epoxomicin (at the doses indicated), and they were then harvested and the cFLIP content was analysed in western blots. b BT-474 cells were transfected with either the siRNA oligonucleotides targeting Itch/AIP4 or the non-targeting RNA oligonucleotide (scrambled) for 48 h as described in the “Materials and Methods”. Subsequently, the cells were treated with SAHA (5 μM) for 8 h and then cFLIP and Itch/AIP4 expression was analysed in immunoblots

    cFLIP down-regulation following SAHA treatment is responsible for the sensitization of breast cancer cells to TRAIL. a BT-474 cells were transfected with either different siRNAs directed against the cFLIP isoforms or the non-targeting RNA oligonucleotide (scrambled) as described in the “Materials and Methods”. After 24 h, the cells were treated with TRAIL (500 ng/ml) for a further 15 h and apoptosis was then measured as the percentage of cells with subG1 DNA content. The results show the mean and S.E.M. of three independent experiments. To verify protein knockdown, cells were harvested 24 h after transfection and the cFLIP levels were assessed in immunoblots. b. BT-474 cells overexpressing Cflipl (pBABE-FLIPL) or control cells (pBABE) were treated with SAHA for 8 h at the doses indicated. After this time, TRAIL (500 ng/ml) was added to some cultures for 15 h. Apoptosis was measured as the percentage of cells with subG1 DNA content and the results show the mean and range of two independent experiments. Western blots show the cFLIP levels after SAHA treatment in pBABE and pBABE-FLIPL cells.

    Differential effects of HDAC inhibitors on histone and tubulin acetylation. Immunofluorescence analysis of histone H3 (K9ac/K14ac) and tubulin acetylation in HeLa cells treated for 4 h with vehicle, SAHA (10 μM), tacedinaline (50 μM), PCI-24781 (20 μM. (a) Mapping of histone acetylation in K562 cells treated with HDAC inhibitors by LC-MS/MS. Cells were treated with TSA (10 μM), SAHA (5 μM), PCI-24781 (2 μM), tacedinaline (50 μM) for 6 h. Histones were extracted from cells and acetylated peptides were quantified after isobaric tagging.
    如果需要长期保存,请于零下二十度低温保存。
    禁止用于人体及ZL!

    特定的存储和包装每个产品的信息在产品说明书上都有注明 。大多数Selleck产品,在推荐的条件下存储可稳定保存两年。产品有时建议的储存温度不同,大多数建议储存在-20 ° C ,抗体及蛋白等产品建议-60℃。YZ剂属于化学试剂,可在常温下运输储存两周左右。即使如此,我们保证产品的出货量将保持产品质量的条件下,一般都会放入冰袋。望阁下收到产品后,请按照产品数据表建议适当存储。



    退换货政策         
     1、 退换货只针对已付款用户。一张订单Selleck只提供一次退换货服务,为了确保您的权益,请考虑周全后与我们联系。         
     2、请您确保退换货时,商品、配件、赠品及各种包装完整。         
     3、因您个人原因造成的商品损坏(如自行使用、分装、受潮、变质、非原物品的等)将不予退换。           
     4、Selleck目前只支持商品一换一服务,换货时无法加定商品。         
     5、如您购买商品时Selleck上海办事处已向您提供发票,则办理退货或订单金额发生变更的换货时,请将发票随商品一同返还给Selleck南京办事处,赛导通生物科技(南京)有限公司,请您妥善保管发票,如发票丢失,将无法办理退换货。         
     6、您的订单若办理退换货,运费金额会在您的实际退款中扣除。
    温馨提示:不可用于临床ZL。
  • 信息声明:本产品供应信息由仪器网为您整合,供应商为(赛导通生物科技(南京)有限公司),内容包括 (现货供应,美国进口,Vorinostat (SAHA) ,目录号 S1047,CAS号:149647-78-9, HDAC-HSP-Aurora ,HDAC YZ剂,HDAC inhibitors)的品牌、型号、技术参数、详细介绍等;如果您想了解更多关于 (现货供应,美国进口,Vorinostat (SAHA) ,目录号 S1047,CAS号:149647-78-9, HDAC-HSP-Aurora ,HDAC YZ剂,HDAC inhibitors)的信息,请直接联系供应商,给供应商留言!
    供应商产品推荐
      您可能感兴趣的产品